Monoclonal antibody · Antagonist of CTLA-4 · developed by Xilio Development
Vilastobart is a humanized, Fc-engineered monoclonal antibody with masked antigen-binding regions that are activated by proteases upregulated in the tumor microenvironment. It binds CTLA-4 on T-cells, blocking its inhibition of T-cell activation, and is being studied in advanced solid tumors, including in combination with atezolizumab.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04896697 | Phase 1/2 | Advanced Solid Tumor | Completed | XLO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumor
Updated Nov 1, 2026. Something wrong or missing? Report it on the XLO page.
See XLO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XLO catalysts and pipeline →